european journal
of gynaecological oncology
an International Journal
| Editors-in-Chief |
A. Onnis
Montréal (CND) |
P. Bösze
Budapest (Hungary) |
Associate Editors
| M. Marchetti |
| Montréal (CND) |
Assistant Editor
J. Wilson
San Diego - CA (USA)
| Editorial Board
|
Allen H.H., London, Ontario (Canada)
Anteby S.O., Jerusalem (Israel)
Audet-Lapointe P., Montreal (Canada)
Ayhan A., Ankara (Turkey)
Balat O., Graziantep (Turkey)
Barber H.K., New York, NY (USA)
Basta A., Krakow (Poland)
Bender H.C., Dusseldorf (Germany)
Benedetti Panici P.L., Rome (Italy)
Charkviani T., Tbilisi (Georgia)
De Oliveira C.F., Coimbra (Portugal)
Dexeus S. Jr., Barcelona (Spain)
Di Paola G.R.,Buenos Aires (Argentina)
Di Re F., Milan (Italy)
Di Saia P., Orange, CA (USA)
Fuller A.F. Jr., Boston, MA (USA) |
Geisler H.E., Indianapolis, IN (USA)
Gerbaulet A., Villejuif (France)
Gorins A., Paris (France)
Heintz A.P.M., Utrecht (The Netherlands)
Ioannidou-Mouzaka L.,Athens (Greece)
Jordan J.A., Birmingham, England (UK)
Karseladze A.I., Moscow (Russia)
Klastersky J., Bruxelles (Belgium)
Kubista E., Vienna (Austria)
Kudelka A.P., Houston, TX (USA)
Maggino T., Padua (Italy)
Markowska J., Poznan (Poland)
Marth C., Innsbruck (Austria)
Massuger Leon F.A.G.,
|
Menczer J., Savyon (Israel)
Monsonego J., Paris (France)
Pinotti A., São Paulo (Brazil)
Piura B., Beer Sheva (Israel)
Piver S.M., Buffalo, NY (USA)
Rakar S., Ljubljana (Slovenia)
Raju K.S., London, England (UK)
Shepherd J.H., London, England (UK)
Stelmachów J., Warsaw (Poland)
Tjalma W., Antwerpen (Belgium)
Ungár L., Budapest (Hungary)
Vermorken J.B., Edegem (Belgium)
Vîrtej P., Bucharest (Romania)
Wang P.-H., Taipei (Taiwan)
Winter R., Graz (Austria)
Yokoyama Y., Hirosaki (Japan) |
Publishing Organization (M. Morsani):
I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc - Apt # 212 - Montréal,
Qué. H3W 2H3 (Canada)
Tel. +514-4893242 - Fax +514-4854513 - E-mail: canlux@mgroup-online.com
- www.irog.net
Editorial Office (M. Critelli):
Galleria Storione, 2/A - 35123 Padua (Italy) - Tel. (39) 049 8756900 -
Fax (39) 049 8752018
|
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN
0392-2936) publishes original peer reviewed works in the fields of female
genital cancers and related subjects and also proceedings of gynecologic
oncology society meetings all over the world. The Journal is covered by
CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/
Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.
European Journal of Gynaecological
Oncology
www.irog.net
General Information
The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936)
publishes original peer reviewed work, preferably brief reports, in the
fields of female genital cancers and related subjects – prevention,
early detection, epidemiology, pathology, diagnosis, management –
and also proceedings of Gynaecologic Oncology Society meetings all over
the world.
The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT,
INDEX MEDICUS, MEDLINE,
EMBASE/ Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.
AIMS AND SCOPE
The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is dedicated to publishing
editorial articles in the “Distin-guished Expert Series” and
original research papers, case reports, letters to the Editor, book reviews
and newsletters.
The Journal was founded in 1980 – the second gynaecologic oncology
hyperspecialization journal in the world. Its aim is the dif-fusion of
scientific, clinical and practical progress and knowledge in female neoplastic
diseases in an interdisciplinary approach among gynaecologists, oncologists,
radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists
and so on.
ANNOUNCEMENTS regarding meetings, postgraduate courses
and symposia will be accepted 6 months before publication and will be
published free of charge.
BOOK SAMPLES for review should be sent to the Editorial
offices in Montréal or in Padova.
COPYRIGHT: the Journal has been registered with the Copyright
Clearance Center, Inc. Reproductions are not allowed without the written
consent of the Publisher. All photocopy fees should be paid to the Copyright
Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA stating
the ISSN number, the volume and the first and last page numbers of each
article copied.
ADVERTISING INFORMATION: advertising orders and inquiries
may be sent to: I.R.O.G. CANADA Inc., Publisher, 4900 Côte St. Luc,
Apt. 212, Montréal (Quebec) Canada H3W 2HS, Tél. 514.4893242-4893640
- Fax 514.4854513 - E-mail: canlux@mgroup-online.com - www.irog.net
RESPONSIBILITY: although every effort is made by the
editorial staff and the printer to eliminate misleading or inaccurate
infor-mation, the publisher accepts no responsibility for the consequences
of faultful or incorrect information. The authors recognize that the editor
and publisher have no responsibility and are indemnified against any liability
or claim that may result from the publication of misleading or incorrect
data.
SUBSCRIPTION INFORMATION
The Journal is published bimonthly (January, March, May, July, September
and November); one volume per year. Subscriptions start from January and
are automatically renewed if not cancelled by the end of September.
Subscriptions include six issues per year plus supplements, monographs
and all official communications of Meetings, Courses, Symposia and all
scientific activities of Gynaecologic Oncology Societies all over the
world.
Subscriptions are entered with prepayment only. The annual
subscription is $390 US for Institutions, $200 US for Individuals. For
airmail add $30, for receipt add $10 US. Single copy prepaid cost $95
US.
Send subscription requests with cheque or credit card payment (Amex -
Visa - Diner’s - Master Card) to I.R.O.G. CANADA Inc., 4900 Côte
St. Luc, Apt. 212, Montréal, Québec H3W 2H3 Canada. Only
US Funds are accepted. No bank transfers.
Claims for missing issues can be honoured up to six months.
Changes of address: allow six weeks for all changes to
become effec-tive. All communications should include both old and new
addresses (with postal codes) – better if accompanied by a mailing
label from a recent issue – and should be sent to the printer: La
Garangola, Via E. Dalla Costa 6, 35129 Padova (Italy) or by Fax +39.049.7806580.
Claims should be made within six months of publication date.
Duplicate copies will not be sent to replace those undelivered through
failure to notify of change of address.
Single copies and back issue and volume information is available from
the printer, La Garangola, Padova, Tel. +39.049.8075557, Fax +39.049.7806580.
Certain back issues may only be available as photocopies of the originals.
All other business correspondence including orders for offprints and advertising
space and any communication and requests should be addressed to I.R.O.G.
CANADA Inc., 4900 Côte St. Luc, Apt. 212, MONTRÉAL, QUÉBEC
H3W 2H3 (Canada), tel. (514) 4893242, fax (514) 4854513.
IN ALL LEGAL MATTERS THE COURT OF MONTREAL IS COMPETENT
European Journal of Gynaecological
Oncology
www.irog.net
Instructions to Authors
SUBMISSION OF MANUSCRIPTS
Papers should be submitted to A. ONNIS Editor-in-Chief of the EUROPEAN
JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 4900 Côte St. Luc, Apt. 212
MONTREAL, QUÉBEC H3W 2H3 (Canada) - Tel. +514-4893242 - Fax +514-4854513,
or Galleria Sto-rione 2/A - 35123 PADOVA (Italy) - Fax +39-049-8752018.
Editorial articles for publication in the “Distinguished Expert
Series” should be submitted to P. Bösze, Editor-in-Chief of
this section, Department of Gynecology, Saint Stephan Hospital, 1096 Budapest,
Nagyvárad tér 1, Telephone (36-1) 275 2172, Fax (36-1)
275 2172, E-mail: bosze@axelero.hu
When a manuscript is submitted, an acknowledgement card is sent to the
corresponding author within two or three weeks.
Submitted papers are reviewed by the Editor-in-Chief and his Peer Referees.
Authors may be required to modify the manuscript according to the reviewers’
suggestions.
Manuscripts accepted for publication will be copyedited by the editorial
staff for typographical and grammatical mistakes and to guarantee clarity
and conciseness.
Publication time will be the shortest possible based
on scientific and publishing needs. Manuscripts submitted for
publi-cation cannot be returned.
Published papers will become property of the Journal and copyrighted under
I.R.O.G. CANADA Inc.
After six months no grievances will be accepted regarding published articles.
All statements are the responsibility of the authors. Product dosages,
indications and methods referred to in the papers reflect the author’s
experience. No responsibility is assumed by the Editor-in-Chief or the
Publisher for any damage from use of any products, operation methods or
instructions contained in the published materials.
Trade names, trademarks, etc. are protected by the law and regulations.
The Editor-in-Chief and the Publisher cannot accept any legal responsibility
for any errors or omissions that may be made in press, particularly for
information about drug dosage and appli-cation thereof contained in the
Journal. Consult the prescribing information before administering any
drug.
MANUSCRIPT REQUIREMENTS
The Journal follows the “Uniform requirements for manuscripts submitted
to biomedical journals” published in the New England Journal of
Medicine 1991, 324, 424-8 and in the British Medical Journal 1991, 302.
Three manuscripts, typed and double spaced should be
submitted with an electronic disk, formatted in Word for Macintosh
or Windows, version 6.0. Manuscripts without an electronic disk
will not be accepted. A cover letter signed by all authors must
state that all authors who have participated in the work take responsibility
for the manuscript which has never been pub lished or submitted for publication
elsewhere. Without a cover letter the publication will not be
possible. Name, address and phone/fax numbers of the Corresponding Author,
responsible for revision and approval of the proofs, should be indicated.
Full-length articles should not exceed 8 printed pages including tables
and references.
After the title page (full title and names of authors,
institutions, eventual acknowledgement for financial support, running
title of no more than 60 characters or spaces), original works should
be arranged in the conventional order: Summary (purpose of investiga-tion,
methods, results, conclusion - about 150 words), Key words, Content
(a 20-word summary), Introduction, Materials and Methods, Results,
Discussion, Conclusion, Acknowledgement (if any), References, Tables,
Legends.
Authors should supply a complete address for reprint requests.
In the text only standard abbreviations can be used and must be avoided
in the title. The full term for which an abbreviation stands should precede
its first use in the summary and text unless it is a standard unit of
measurement.
Authors must give their complete professional identifications
and affiliations, including all academic titles and positions.
Letters to the editor should be brief (500 words or less)
and offer objective, constructive and educational criticism of published
material. The editor reserves the right to publish.
Figures: Two original copies (not negatives) of each
figure are requested. Each figure should have a label on the back indicating
its number, author’s name and top of the figure. Do not write on
the back of the figures and do not mount them on cardboard. If
sending colour pictures advise if they must be printed in colour or black
and white (colour costs ten times more).
Legends should be typed on a separate page with Arabic
numerals corresponding to the illustrations.
Tables should be titled, typed in double space on separate
pages and numbered in Arabic numerals in the order of their first cita-tion
in the text. Do not use internal rules. Only standard, universally understood
abbreviations should be used.
References should be numbered consecutively in the order in which
they are first mentioned in the text. Identify references in
the text, tables, and legends by Arabic numerals in parentheses.
Use the style of the examples below, which are based with slight modifications
on the format used by the U.S. National Library of Medicine in Index Medicus.
The titles of journals should be abbreviated according to the style used
in Index Medicus.
References must be verified by the Author(s) against the original documents.
Examples of correct forms of references are given below:
Articles in Journals: Authors’ surname and initials
(if more than six names, give six followed by “et al.”), Title,
Abbreviated Journal Title, Year of Publication, Volume, Issue and first
page.
Books: Authors’ surname and initials, title of
the book and title of chapter, in: Title, Editor(s), Place, Publisher,
Year, Page.
Acknowledgments will be limited to appropriate professionals
who were contributors to the paper.
PROOFS revised by the editorial staff will
be sent to the corresponding author and should be checked and returned
within ten days. The corresponding author is responsible for detecting
typesetting errors. After this deadline the proofs will be considered
approved. Only essential corrections should be made; extensive changes
will be charged to the authors.
BUSINESS MATTERS
The Journal has no commercial advertisements.
Authors will be expected to contribute to the printing expenses,
tables, figures and postage. For every published article a copy
of the Journal will be provided free of charge. Only payments
in US dollars will be accepted. No bank transfers.
Reprints should be requested with the form enclosed
with the acceptance letter. No free reprints will be supplied.
© By I.R.O.G. CANADA INC. - Publisher - Editorial office
4900 Côte St. Luc - Apt. 212 - Montréal Québec H3W 2H3
(Canada) - Tel. (514) 4893242-4893640 - Fax (514) 4854513 - Printed in Italy
by “La Garangola” - Via E. Dalla Costa, 6 - 35129 Padua (Italy)
- Responsible Director: Prof. Antonio Onnis M.D. - Authorization of Padua’s
Court n. 633 - 28-6-1979 |
| |
|
 European
Journal of Gynaecological Oncology - Vol. XXVII, n. 5, 2006 |
|
| |
|
| CONTENTS |
|
| DISTINGUISHED EXPERT SERIES |
|
| Ovarian cancer Stage IIIC. Consequences of
treatment level on overall and progression-free survival |
209 |
H. Oksefjell, B. Sandstad, C. Trope - Montebello,
NORWAY
The aim of the study was to investigate the influence of hospital
level (primary vs secondary care centre), number and timing of surgery
and chemotherapy on how radical the surgery was at primary treatment
of epithelial ovarian cancer Stage IIIC. |
|
| Down-regulation of E-cadherin is closely associated
with progression of cervical intraepithelial neoplasia (CIN), but
not with high-risk human papillomavirus (HPV) or disease outcome in
cervical cancer |
215 |
M. Branca, C. Giorgi, M. Ciotti, D. Santini,
L. Di Bonito, S. Costa, A. Benedetto, D. Bonifacio, P. Di Bonito,
P. Paba, L. Accordi, L. Mariani, S. Syrjänen, C. Favalli, K.
Syrjänen, on behalf of the HPV-PathogenISS Study Group - Turku,
FINLAND
Down-regulation of E-cadherin was closely associated with progressive
CIN and cell proliferation, but did not directly correlate with oncogenic
HPV type and did not predict survival in cervical cancer. |
|
 |
|
| EDITORIAL ARTICLE |
|
| Definitive and palliative radiotherapy for
cervix cancer in the elderly |
225 |
Breast cancer treatment - later pregnancy
and survival M. Kasum - Zagreb, CROATIA
The increasing population of women with BC who delay childbearing
may have concerns regarding the effect of treatment on later pregnancy,
as well as the influence of pregnancy on the prognosis of disease
and their survival. |
|
 |
|
| ORIGINAL ARTICLES |
|
| Radiation therapy with concomitant and adjuvant
cisplatin and paclitaxel in high-risk cervical cancer: long-term follow-up |
231 |
P.A. Argenta, R. Ghebre, K.E. Dusenbery,
M.D. Chen, P.L. Judson, L.S. Downs Jr., L.F. Carson - Minneapolis,
MN (USA)
Radiation potentiation with cisplatin and paclitaxel results in prolonged
survival in high-risk cervical cancer, but toxicity may be prohibitive. |
|
| Radioguided occult lesion localisation in combination
with detection of the sentinel lymph node in nonpalpable breast cancer
tumours |
236 |
P. Strnad, L. Rob, M.G. Halaska, J. Chod,
A. Zuntova, Z. Moravcova - Prague, CZECH REPUBLIC
The combination of ROLL and SLNB is a possible and safe procedure
and when compared with the hook-wire techinque, the amount of tissue
excision is similar. |
|
| Efficiency of three surgical procedures in
eliminating high-risk human papillomavirus infection in women with
precancerous cervical lesions |
239 |
N. Janc?ar, S. Rakar, M. Poljak, K. Fujs,
B.J. Kocjan, E. Vrtac?nik-Bokal - Ljubljana, SLOVENIA
Laser vaporization, large loop excision of the transformation zone
and conization are effective in eliminating high-risk HPV infection. |
|
| Effective chemoradiotherapy protocol with 5-fluorouracil
for cervical squamous cell carcinoma in vitro |
243 |
T. Tanaka, K. Yukawa, N. Umesaki - Wokayama,
JAPAN
5FU acts as a radiosensitizer for cervical squamous cell carcinoma
and 5FU-sensitivity is reduced in irradiated cells. |
|
| Trastuzumab in metastatic breast cancer |
247 |
F. Tomao, E. Miele, G.P. Spinelli, M. Russillo,
G. La Ferla, S. Tomao - Rome, ITALY
Trastuzumab, a humanized monoclonal antibody directed against the
HER2 protein, has been shown to be an efficacious and well tolerated
treatment for HER2-overexpressing metastatic breast cancer, both as
a single agent and when it is used in combination with chemotherapy. |
|
| Clinicopathological features of unusual vascular
lesions of the pelvis, retroperitoneum and colon in females: a report
of five cases and review of the literature |
250 |
E. Kairi-Vassilatou, D. Grapsa, K. Kontogianni-Katsarou,
V. Smyrniotis, D. Hasiakos, A. Kondi-Pafiti Agatha - Athens, GREECE
Five cases of unusual vascular lesions of the female pelvis, retroperitoneum
and colon are presented. |
|
| Proliferative effects of different hormone
regimens on mammary glands in ovariectomized rats |
256 |
T. Cirpan, O. Iscan, M.C. Terek, S. Ozsener,
L. Kanit, S. Pogun, O. Zekioglu, S. Yucebilgin - Izmir, TURKEY
The proliferative effects of different hormone regimens and estrogen
receptor modulation on mammary glands in a rat model of surgical menopause
are compared. |
|
| Wire localisation biopsy of non-palpable breast
lesions: reasons for unsuccessful excision |
262 |
E. Kouskos, G.P.H. Gui, D. Mantas, K. Revenas,
N. Rallis, Z. Antonopoulou, E. Lampadariou, H. Gogas, C. Markopoulos
- Athens, GREECE
An uncommon problem of needle-wire localisation is the failure to
identify, localise or excise the breast lesion. In this review article,
factors that contribute to the failed needle localisation procedure
are presented. |
|
| Cervical-vaginal disease in HIV immunosuppressed
patients: management and present screening programme |
267 |
L. Di Stefano, G. Coppola, S. Moro, E. Colageo,
A. Cellini, G. Coletti - L’Aquila, ITALY
The correlations between cervical lesions, the role of HPV and the
clinical and immunological aspects of HIV infection and inflammatory
cervical-vaginal disease were studied. |
|
| Endometriosis and possible malignant transformation |
271 |
M. Gojnic, V. Dugalic, V. Jeremic, N. Popovic,
Lj. Arsenijevic - Belgrade, SERBIA AND MONTENEGRO
Endometriosis is a benign condition characterized by infiltrative
growth with a very small, if any, possibility of becoming malignant.
Conservative surgery is still one of the main therapy modes, but is
mainly reserved for mild cases of the disease. |
|
| Uterine bizarre epithelioid lipoleiomyoma with
a myxoid stroma |
273 |
K. Takeuchi, S. Kitazawa, T. Tsujino, S.
Wakahashi, T. Maruo - Kobe, JAPAN
A rare case of uterine bizarre epithelioid lipoleiomyoma with nuclear
atypia within a myxoid stroma is described. |
|
| Surgical management of nipple discharge |
275 |
C. Markopoulos, D. Mantas, E. Kouskos, Z.
Antonopoulou, K. Lambadariou, K. Revenas, A. Papachristodoulou - Athens,
GREECE
Nipple discharge is reported in 2.5 to 3% of women with breast carcinoma.
Breast carcinoma is found in approximately 8% of surgically treated
patients presenting with bloody nipple discharge. |
|
| Amerindian women of the Brazilian Amazon and
STD |
279 |
E.B. Brito, I.D.C. Silva, J.N. Stávale,
E. Taromaru, R.C. Menezes, S.J. Martins - Parakanä, BRAZIL
Papanicolaou tests, PCR for HPV, C. trachomatis, HSV-1/2 and N. gonorrhoea,
and Hybrid Capture II were performed for high- and low-risk HPV groups
during screening for cervical cancer in 49 women of the Parakana tribe. |
|
| DCIS histopathology from a historical perspective |
282 |
A.C. Goussia, D.G. Stefanou, E.C. Karaiossifidi,
N.J. Agnantis - Athens, GREECE
Historically the definition and terminology associated with the histological
types of DCIS have caused confusion. Some data in
the literature are reviewed. |
|
| Spontaneous transient rise of CD34 cells in
peripheral blood after 72 hours in patients suffering from advanced
malignancy with anemia: Effect and prognostic implications of treatment
with placental umbilical cord whole blood transfusion |
286 |
N. Bhattacharya - Calcutta, INDIA
Umbilical cord whole blood transfusion is safe in cancer patients
with anemia. A sustained rise of CD34 levels in some patients may
have a positive prognostic effect. |
|
 |
|
| CASE REPORTS |
|
| Third stage ovarian carcinoma - case report:
the necessity of a multidisciplinary approach to treatment |
291 |
E.M. Messalli, C. Scaffa, G. Mainini, M.
Rotondi, E. Pecori, L. Cobellis - Naples, ITALY
A case of third-stage ovarian carcinoma is presented and the necessity
of a multidisciplinary approach to treatment is discussed. |
|
| A giant uterine leiomyoma simulating an ovarian
mass in a 16-year-old girl: a case report and review of the literature |
294 |
D. Grapsa, V. Smyrniotis, D. Hasiakos, K.
Kontogianni-Katsarou, A. Kondi-Pafiti, Athens, GREECE
A case of a giant uterine leiomyoma in a 16-year-old girl, which was
preoperatively misdiagnosed as an ovarian malignancy, is reported. |
|
| Recurrent endometrial stromal sarcoma after
treatment with high-dose chemotherapy and autologous stem-cell support:
A case report |
297 |
P. Klaritsch, O. Reich, S. Regauer, T. Bauernhofer
- Graz, AUSTRIA
High-dose chemotherapy seems to be ineffective in patients with endometrial
stromal sarcomas. |
|
| Metastases of the digestive tract and ovarian
tumors - or vice versa: an analysis |
299 |
M. Gojnic, V. Dugalic, V. Jeremic, D. Filimonovic,
N. Popovic - Belgrade, SERBIA AND MONTENEGRO
By analyzing ovarian carcinoma cases at three institutions interesting
data were obtained: in 38% of the cases metastatic changes were present. |
|
| Case study of a pregnant woman with decidualized
ovarian endometriosis whose preoperative findings suggested malignant
transformation |
301 |
H. Iwamoto, M. Suzuki, N. Watanabe, M. Minai,
S. Hirata, K. Hoshi - Yamanashi, JAPAN
A case of decidualized ovarian endometriosis in a pregnant woman is
reported. The findings suggest that decidualization of endometriosis
can be differentiated preoperatively from malignant transformation. |
|
| Mucinous adenocarcinoma arising from the gastrointestinal
epithelium in benign cystic teratoma of the ovary - Case Report |
304 |
M. Güney, B. Oral, F. Demir, M. Özsoy,
N. Kapucuog?lu - Isparta, TURKEY
A rare case of adenocarcinoma arising from the gastrointestinal epithelial
elements of BCTO based on microscopic examination and immunohistochemical
studies is presented. |
|
| Double laparotomy wound recurrence of endometrial
carcinoma |
307 |
G.C. Balbi, A. Cardone, A. Monteverde, M.
Passaro, L. Montone, R. Rossiello, S. Visconti, M. Battisti, E. Cassese,
I. Landino - Naples, ITALY
A case of a 65-year-old woman who had two recurrences in an abdominal
incisional scar after total hysterectomy is reported. |
|
| Primary leiomyoma of the ovary in a young woman:
literature review and report of a case |
310 |
E.E. Ozcimen, M. Oktem, H.B. Zeyneloglu,
B.H. Ozdemir, E. Kuscu - Ankara, TURKEY
A case of ovarian leiomyoma in a 32-year-old virgin with the complaint
of dysmenorrhea for six months is presented. |
|
| Female adnexal tumor of probable Wolffian origin:
clinicopathological, immunohistochemical and cytofluorimetric analyses
of a 22-year-old virgin. Case report |
313 |
G.C. Balbi, L. Del Piano, D. Labriola, S.
Visconti, A. Monteverde, M. Passaro, R. Monaco, A. Cardone, R. Rossiello,
S. Panariello, L. Montone - Naples, ITALY
A case of the youngest patient affected by FATWO is reported. At laparotomy
the left adnexa, deformed by a well-capsulated mass, was totally removed
and sent to the pathologist with a specimen of peritoneal fluid and
the omentum. |
|
 |
|
|